Slow Capital Inc. bought a new position in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 18,083 shares of the company's stock, valued at approximately $4,377,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of ONC. Farther Finance Advisors LLC bought a new stake in BeOne Medicines during the second quarter worth $39,000. Signaturefd LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at approximately $49,000. Parallel Advisors LLC acquired a new position in BeOne Medicines during the 2nd quarter worth approximately $59,000. Avanza Fonder AB bought a new position in BeOne Medicines in the 2nd quarter valued at approximately $199,000. Finally, Aaron Wealth Advisors LLC acquired a new stake in BeOne Medicines in the second quarter valued at approximately $200,000. Institutional investors and hedge funds own 48.55% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on ONC. Morgan Stanley boosted their price target on BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a report on Friday, June 27th. Barclays assumed coverage on shares of BeOne Medicines in a research note on Thursday, September 18th. They set an "overweight" rating and a $385.00 price target for the company. JPMorgan Chase & Co. lifted their target price on BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Zacks Research raised BeOne Medicines from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 18th. Finally, Royal Bank Of Canada lifted their price objective on BeOne Medicines from $349.00 to $364.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BeOne Medicines has an average rating of "Moderate Buy" and an average price target of $336.30.
Check Out Our Latest Report on BeOne Medicines
BeOne Medicines Price Performance
Shares of NASDAQ ONC opened at $344.53 on Tuesday. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The firm has a market cap of $37.76 billion, a price-to-earnings ratio of -199.15 and a beta of 0.31. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $170.99 and a 1-year high of $355.30. The stock has a fifty day simple moving average of $319.57 and a two-hundred day simple moving average of $274.54.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. Analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.
Insider Activity
In other BeOne Medicines news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $337.00, for a total transaction of $898,105.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Titus B. Ball sold 122 shares of BeOne Medicines stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $326.76, for a total value of $39,864.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 181,315 shares of company stock valued at $54,839,498. Corporate insiders own 6.62% of the company's stock.
About BeOne Medicines
(
Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
